How Mushroom Prebiotics Influence Brain Function Through the Gut

Mushrooms & Gut Health

5% mushroom diet, measurable brain changes

A diet containing just 5% by weight of Agaricus bisporus (white button or portobello) mushrooms significantly prevented brain oxidative stress markers in stressed mice, while shifting their gut bacteria toward SCFA-producing families. The gut-mediated explanation is the leading interpretation — but the study measured both changes without proving one caused the other.

García-Sanmartín et al., Antioxidants, 2022

4 links, 4 evidence grades

the pathway runs fiber → bacteria → butyrate → brain. Human data is strong for the first two links, absent for the third, and animal-only for the fourth

Butyrate crosses the BBB

a short-chain fatty acid produced when gut bacteria ferment mushroom fiber. In the general SCFA literature it reduces neuroinflammation and supports BDNF — this step has not been measured after mushroom feeding

p = 0.001 in humans

a 4-week trial in 80 adults found significantly higher intestinal butyrate on a mushroom diet than placebo — human evidence for the fermentation step, though not for the brain step (Nishimoto et al., 2022)

García-Sanmartín et al., Antioxidants, 2022

View as image ↗

More than 90% of the body's serotonin is produced in the gut, not the brain. The enterochromaffin cells lining the digestive tract synthesize and secrete serotonin in response to signals from the gut bacteria living nearby. When those bacteria are well-fed and diverse, serotonin precursor production runs efficiently. When they are not, the downstream effects reach the brain.

This is where mushroom prebiotics enter the picture. The structural compounds in mushrooms — beta-glucans, chitin, hemicellulose — are not digested by human enzymes. They pass largely intact into the colon, where gut bacteria ferment them. That fermentation produces short-chain fatty acids (SCFAs), particularly butyrate. Butyrate crosses the blood-brain barrier, and inside the brain it reduces neuroinflammation, supports the production of brain-derived neurotrophic factor (BDNF), and modulates the stress response pathways that connect gut health to mental health.

That is the proposed pathway, and it is worth stating up front that it is a chain of four separate claims rather than one finding. Some of those links are backed by human trials; one has never been measured in the context of mushrooms at all. Sorting out which is which is the point of this article, because the pathway is frequently described as though the whole chain were established.

This prebiotic-to-brain pathway operates alongside the more widely discussed direct mechanisms of functional mushrooms (hericenones crossing the BBB, ganoderic acids acting on inflammatory pathways). The gut-mediated route may account for a meaningful portion of the brain effects attributed to mushroom consumption — including effects from common culinary mushrooms like button and portobello that have no traditionally recognized "brain" compounds at all.

For the broader overview of mushrooms and the gut-brain axis, see Mushrooms and the Gut-Brain Axis: How Gut Health Affects Your Mind and the pillar at Mushrooms as Prebiotics: How They Feed Your Gut Bacteria.

What Makes Something a Prebiotic (And How Mushrooms Qualify)

A prebiotic, in the strict definition, is a substrate that is selectively used by host microorganisms and confers a health benefit. To qualify, a compound must resist digestion by host enzymes, be fermented by gut microbiota, and produce a demonstrable beneficial effect through that fermentation.

Mushroom cell walls contain several compounds that meet this definition. Beta-glucans, the branched polysaccharide chains built from glucose units with beta-1,3 and beta-1,6 linkages, are not broken down by human digestive enzymes. Chitin, the structural polymer forming the rigid scaffold of mushroom cell walls, is equally resistant to digestion. Hemicellulose and other polysaccharide components follow the same pattern.

A 2024 review by Kulshreshtha in Probiotics and Antimicrobial Proteins argued explicitly for classifying mushrooms as prebiotic agents for healthcare applications, citing the selectivity of mushroom fiber fermentation and the documented downstream health effects as meeting the prebiotic definition.^[1] A 2020 review by Liu and colleagues specifically linked mushroom prebiotic compounds to gut microbiota-mediated health outcomes — establishing the mechanistic chain that connects mushroom consumption to systemic effects via the microbiome rather than via direct compound absorption.^[7]

The Four-Step Pathway: How Mushroom Fiber Reaches Your Brain

The prebiotic-to-brain pathway for mushroom compounds can be mapped in four steps:

1. Non-digestible fiber travels undigested to the colon. Mushroom beta-glucans, chitin, and hemicellulose pass through the small intestine without being absorbed or broken down, because the relevant enzyme systems are absent in humans. They arrive in the large intestine largely intact.

2. Gut bacteria ferment these fibers, producing short-chain fatty acids. Specific gut bacteria — including Akkermansia, Bifidobacterium, Bacteroides, and Ruminococcus species — express the enzymes needed to cleave and ferment beta-glucan and chitin chains. The primary fermentation products are the short-chain fatty acids: butyrate (4 carbons), propionate (3 carbons), and acetate (2 carbons).

3. Butyrate crosses the blood-brain barrier. Among the three SCFAs, butyrate has the highest brain relevance because it crosses the blood-brain barrier via monocarboxylate transporters. Inside the brain, it acts as an HDAC inhibitor (a type of gene expression regulator), reduces neuroinflammatory signaling, and increases the production of BDNF in hippocampal and prefrontal cortex cells.

4. BDNF and anti-inflammatory signaling improve brain function. BDNF supports synaptic plasticity, neuron survival, and the formation of new neurons in the hippocampus — the brain region most directly involved in learning, memory, and mood regulation. Reduced neuroinflammation from butyrate decreases IL-6 and other pro-inflammatory cytokines that are elevated in depression, anxiety, and cognitive decline.

This pathway operates separately from vagus nerve signaling (another gut-brain communication route) and from the direct absorption of mushroom compounds that cross the BBB on their own. All three routes may be active simultaneously.

The four steps are usually presented as a single established mechanism. They are not. Each step is a separate empirical claim, and the evidence behind them differs sharply — strong human data for the first two, essentially none for the third as it applies to mushroom fiber, and animal-only data for the fourth. That asymmetry is the most important thing to understand about this topic, and it is what the rest of this article works through.

Four Links · Four Different Evidence Grades

Where the Mushroom–Gut–Brain Chain Is Actually Proven

The pathway is often presented as a single established mechanism. It is really four separate claims, and they are not equally supported. Human mushroom evidence is strong through link 2, absent at link 3, and animal-only at link 4.

1. 01Mushroom fiber reaches the colon intact

   Beta-glucans, chitin and hemicellulose are not cleaved by human digestive enzymes, so they arrive in the large intestine largely undigested. This is settled biochemistry and the basis for classifying mushrooms as prebiotic substrates.

   Human evidenceRefs 1, 7

   Established in humans — the non-digestibility is the definition, not a finding under test.

2. 02Gut bacteria ferment it into short-chain fatty acids

   Fermentation by SCFA-producing bacteria yields butyrate, propionate and acetate. This is the strongest human link in the chain — and the one most often skipped over in popular coverage.

   Human evidenceRefs 3, 13, 14, 15

   A 4-week parallel-group trial in 80 healthy adults found significantly higher intestinal butyrate on a mushroom diet than placebo (p = 0.001, Hedges’ g = 0.824) and higher propionate (p = 0.020). A separate double-blind RCT (n = 52) shifted colonic microbiota with shiitake beta-D-glucan, and human fecal and IBS microbiomes respond to mushroom substrate ex vivo.

3. 03Butyrate reaches the brain and changes signalling

   Butyrate crosses the blood-brain barrier via monocarboxylate transporters, inhibits HDAC enzymes, and dampens microglial inflammatory signalling — the step that converts a gut event into a brain event.

   Inferred from general gut-brain researchNot established for mushroom fiber

   Well characterised in the general gut-brain and SCFA literature, but no study cited here measured brain butyrate, HDAC activity or BDNF after mushroom feeding. This link is imported, not demonstrated.

4. 04Brain oxidative stress and inflammation fall

   The endpoint people actually care about: measurable protection of the brain under stress.

   Animal onlyRef 4

   A diet of 5% Agaricus bisporus significantly prevented the stress-induced rise in Il-6, Nox-2 and Hmox-1, the loss of catalase and superoxide dismutase activity, and the increase in lipid peroxidation — in mice. The same animals showed increased Akkermansiaceae and Tannerellaceae. No human study has measured a brain endpoint after mushroom prebiotic intake.

Read down the chain: each link is a separate empirical claim. A pathway is only as well-evidenced as its weakest link, and here that is link 3 — the step no mushroom study has actually measured.

SCFA Production: The Mechanistic Core

Short-chain fatty acids are the proposed central mechanism linking mushroom fiber to the brain, and they are also the part of the chain that has been measured most directly. Yin and colleagues' 2020 review in Carbohydrate Polymers established that mushroom polysaccharides specifically enrich gut microbiota diversity and increase SCFA-producing bacterial populations — not just any bacteria, but those that convert dietary fiber into the SCFAs that drive downstream effects.^[2]

The specificity of this effect matters. Different prebiotic fibers feed different bacteria. Mushroom beta-glucans appear to preferentially enrich specific SCFA-producing bacterial genera rather than broadly increasing all gut bacteria. A 2022 review by Ma and colleagues in Critical Reviews in Food Science and Nutrition confirmed this pattern across multiple mushroom species and multiple SCFA-producing bacterial genera — mushroom polysaccharides produce a measurable, directional shift toward SCFA-producing bacteria that is not simply a generic microbiome improvement.^[5]

The review by Yu and colleagues in 2023 specifically traced the pathway from mushroom dietary fiber through SCFA production to intestinal barrier improvement to neurological effects — mapping fiber fermentation not just as a gut health endpoint but as a step in a longer proposed chain reaching the brain.^[8]

Reviews, however, describe what the underlying studies found — and for a long time those underlying studies were almost entirely animal work. That changed with a direct human measurement.

The Human SCFA Trial

Nishimoto and colleagues ran a parallel-group trial in 80 healthy adults, who consumed either a mushroom-containing diet or a placebo diet once daily for four weeks.^[13] The researchers sequenced gut bacteria and measured the intestinal metabolome directly, rather than inferring SCFA production from bacterial composition alone.

The mushroom group ended the trial with significantly higher intestinal butyrate than the control group (p = 0.001, Hedges' g = 0.824 — a large effect) and significantly higher propionate (p = 0.020, g = 0.474). This is the single most important data point for the mushroom prebiotic pathway in humans: it confirms that eating mushrooms raises the SCFA that the rest of the pathway depends on, in people, at a dietary dose, over a realistic timeframe.

Strongest Human Link

Nishimoto et al. (2022) · Frontiers in Nutrition

Population

80 healthy adults, parallel-group design (trial registration UMIN000043979)

Intervention

A mushroom-containing diet once daily for 4 weeks

Comparator

Placebo diet, parallel control group

Finding

Intestinal butyrate was significantly higher in the mushroom group than the control group (p = 0.001, Hedges' g = 0.824), as was propionate (p = 0.020, g = 0.474). Intestinal IgA tended to increase but did not reach significance (p = 0.081), and the IgA rise was strongest in subjects who already had higher SCFA levels at baseline.

positive Confirms the fermentation step in humans, not the brain step — this trial measured gut metabolites and immune markers, not cognition, mood or any brain endpoint. The authors also note the effect size depends on a participant's baseline gut environment.

Nishimoto et al., Frontiers in Nutrition, 2022; 9:1078060

The caveat matters as much as the finding. The effect was conditional on baseline gut composition — the same diet did not do the same thing in every participant. Prebiotic response is individual, and a group-level p-value does not promise an individual result.

Butyrate and the Brain: Why This SCFA Matters Most

Among the three primary SCFAs, butyrate receives the most research attention for brain effects because it is the most active in neural tissue.

An important framing note before this section proceeds. Everything described below comes from the general SCFA and gut-brain literature — studies of butyrate itself, not studies of mushrooms. None of the mushroom research cited in this article measured brain butyrate levels, HDAC activity, or BDNF expression after mushroom feeding. This is the imported link in the chain. It is well characterised in its own right, which is why it is reasonable to propose it, but proposing a mechanism and demonstrating it in the specific case are different things.

With that caveat: butyrate inhibits histone deacetylase (HDAC) enzymes in the brain. HDAC inhibitors increase the accessibility of gene promoters, which in turn increases BDNF gene transcription. More BDNF means more synaptic support, more neuroplasticity, and better protection against the neuronal atrophy that accompanies chronic stress and depression.

Butyrate also suppresses the nuclear factor NF-κB pathway in microglia (the brain's immune cells), reducing production of pro-inflammatory cytokines including IL-6 and TNF-alpha. Chronic elevation of these cytokines is one of the better-documented biological correlates of major depressive disorder, and reduced abundance of butyrate-producing gut bacteria has been reported in depression populations. These are associations drawn from the wider microbiome-psychiatry literature rather than from mushroom trials, and they describe correlation rather than established causation — they are the reason researchers find the mushroom pathway worth investigating, not evidence that it works.

The comprehensive 2023 review by Zhao and colleagues in Biology confirmed that mushroom polysaccharide-microbiota interactions are bidirectional — mushroom fibers shape the bacterial population, and those bacteria in turn shape the metabolite environment (including butyrate levels) in ways that cascade to systemic health effects including neurological outcomes.^[9]

Which Mushroom Fibers Feed Which Bacteria: What the Research Shows

Turkey tail (Trametes versicolor) supplied the earliest direct evidence for human gut microbiota modification. Yu and colleagues in 2013 demonstrated that turkey tail extract significantly altered human fecal microbiota composition in vitro.^[3] In vitro fecal testing is not equivalent to a clinical trial, but it established that turkey tail compounds act on human gut bacteria, not just rodent gut bacteria.

That 2013 result is no longer the only human-derived data point, and the newer work is stronger. Morales and colleagues ran a randomised, double-blind, placebo-controlled trial in 52 adults with untreated mild hypercholesterolemia, giving a beta-D-glucan-enriched extract from shiitake (Lentinula edodes) supplying 3.5 g/day of fungal beta-glucans for eight weeks.^[14] The colonic microbiota shifted measurably relative to placebo, with several bacterial genera correlating with cholesterol-related biomarkers.

The same trial is also a useful corrective. It found no significant change in cholesterol, IL-1β, IL-6, TNF-α or oxidised LDL over those eight weeks. Mushroom beta-glucan moved the microbiome without moving the clinical markers the researchers hoped it would move. A microbiota shift is a real effect, but it is an intermediate one — it does not automatically cash out as a health outcome, and this trial is direct evidence of that gap.

Two 2025 studies extend the human-tissue work further. Van den Abbeele and colleagues showed that a mushroom blend restored butyrate production in the microbiomes of IBS patients using an ex vivo fermentation system coupled to human epithelial and immune cell cultures, with downstream improvement in barrier integrity.^[15] Kerezoudi and colleagues fermented Pleurotus eryngii (king oyster) with human fecal microbiota and found the resulting products protected intestinal barrier integrity in healthy human colonic tissue challenged with deoxycholic acid.^[16] Both are ex vivo rather than clinical, and both are small — but both use human material and both land on the barrier-and-butyrate mechanism the pathway depends on.

Oyster mushrooms (Pleurotus ostreatus) show a dual action. A 2023 review by Törős and colleagues documented that oyster mushrooms contain both prebiotic compounds (feeding beneficial bacteria) and antimicrobial compounds (reducing pathogenic bacteria).^[11] This two-directional gut modulation — enriching beneficial species and depleting harmful ones simultaneously — produces a more robust microbiome shift than prebiotic action alone.

A 2023 review by Zhao and colleagues in Frontiers in Nutrition compiled species-specific data on how edible mushroom polysaccharides modulate gut microbiota — covering multiple genera with species-specific bacterial targets and downstream effects.^[12] The broad evidence base, reviewed by Jayachandran and colleagues in 2017, confirms that edible mushrooms as a category — not just exotic medicinal species — consistently alter gut microbiota toward beneficial populations.^[6]

Nguepi and Song's 2020 review, though focused primarily on liver health, documented the prebiotic classification and microbiota modulation of mushroom bioactives through the same mechanism — confirming that the gut-mediated pathway is a general property of mushroom compounds, not a species-specific phenomenon.^[10]

The Agaricus Finding: Brain Protection From an Ordinary Mushroom

The García-Sanmartín 2022 study deserves particular attention because its implications reach well beyond specialized medicinal mushrooms.^[4]

García-Sanmartín and colleagues fed stressed mice diets containing 5% by weight of either Agaricus bisporus (white button mushroom) or Agaricus bisporus var. portobello. These are ordinary culinary mushrooms available in every supermarket — no specialized medicinal properties are typically attributed to them beyond general nutritional value.

Mice subjected to restraint stress showed upregulated Il-6 (an inflammatory cytokine), Nox-2 (a marker of oxidative NADPH oxidase activity) and Hmox-1 (a stress response enzyme), reduced activity of catalase and superoxide dismutase (the brain's own antioxidant enzymes), and increased lipid peroxidation. Three weeks of feeding on the Agaricus-supplemented diets significantly prevented all of these changes.

Alongside the brain results, the mushroom-fed mice showed a shifted microbiome: increased Akkermansiaceae and Tannerellaceae — SCFA-producing bacterial families — and decreased Prevotellaceae, with a large increase in Verrucomicrobia at the phylum level. Notably, the Firmicutes/Bacteroidetes ratio, whose stability is treated as a marker of a healthy diet, did not change.

The Brain Endpoint — Animal Only

García-Sanmartín et al. (2022) · Antioxidants

Population

Mice fed for 12–15 weeks, then subjected to restraint stress

Intervention

Diet supplemented with 5% (w/w) Agaricus bisporus (white button) or A. bisporus brunnescens (portobello)

Comparator

Regular diet, same stress protocol

Finding

Stress-induced upregulation of Il-6, Nox-2 and Hmox-1, loss of catalase and superoxide dismutase activity, and increased lipid peroxidation were all significantly prevented by 3 weeks on the mushroom diets. Microbiota shifted toward SCFA-producing Akkermansiaceae and Tannerellaceae. Body weight was unaffected.

mixed A genuine brain-level result, but in mice, and the gut-mediation is proposed rather than proven — the study measured microbiota changes and brain changes in the same animals without a germ-free control, microbiota transplant, or mediation analysis to show one caused the other.

García-Sanmartín et al., Antioxidants, 2022; 11(4)

That last point deserves emphasis, because it is where popular summaries of this study tend to overreach. The researchers observed two things in the same animals: the microbiome changed, and the brain was protected. They did not demonstrate that the first caused the second. Establishing that would require showing the protection disappears when the microbiota is removed or transferred — for example via germ-free animals or a fecal transplant. Agaricus mushrooms also contain compounds with direct antioxidant activity, including ergothioneine, which offers a competing explanation that this design cannot rule out. The gut-mediated reading is plausible and consistent with the bacterial families involved, but it remains an interpretation.

What the finding does establish is that the effect appears at an ordinary dietary intake of an ordinary supermarket mushroom, rather than requiring a high-dose medicinal extract. For a species-level comparison of mushrooms' prebiotic value, see Which Mushrooms Are the Best Prebiotics? A Species Comparison.

What This Means for the Gut-Brain Research Landscape

The honest summary is that this pathway is well-evidenced at both ends and unmeasured in the middle.

At the gut end, the evidence is genuinely human and genuinely quantitative: mushroom consumption raises intestinal butyrate in a controlled trial,^[13] mushroom beta-glucan shifts human colonic microbiota in a randomised double-blind design,^[14] and human gut communities respond to mushroom substrate ex vivo.^[15] At the brain end, there is one clear animal result showing protection of brain tissue under stress.^[4]

What does not exist, as of this writing, is a controlled human trial that follows the chain end to end — feeding people mushrooms, measuring the resulting SCFA change, and then measuring a brain or cognitive or mood outcome in the same participants. Every article that presents "mushroom prebiotics improve brain function" as a settled human finding is bridging that gap with inference rather than data.

Mushroom Prebiotics → Brain Function

1. Cell & ex vivo human tissuecompleted

   Turkey tail extract altered human fecal microbiota in vitro (2013); mushroom blends restored butyrate in IBS microbiomes and king oyster fermentation protected human colonic tissue (2025). Refs 3, 15, 16.

2. Animal studiescompleted

   A 5% Agaricus diet prevented brain oxidative stress markers in restraint-stressed mice while shifting SCFA-producing bacteria — the only brain-level result in this evidence base. Ref 4.

3. Small human trialscurrent

   An 80-person parallel-group trial raised intestinal butyrate (p = 0.001) and a 52-person double-blind RCT shifted colonic microbiota — but both measured gut endpoints only, never a brain endpoint. Refs 13, 14.

4. Large RCT with a brain endpointmissing

   No trial has fed people mushrooms and measured cognition, mood or a neurological marker alongside SCFA change. This is the missing step that would convert the pathway from plausible to demonstrated.

5. Meta-analysismissing

   Not possible without the trials above. The many reviews in this field synthesise mechanism and animal work, not pooled human brain outcomes.

Human evidence is solid for the gut half of the pathway and absent for the brain half. The reviews that describe this pathway are synthesising mechanism, not pooling human outcome trials — a distinction that is easy to lose when a claim is repeated often enough.

Refs 3, 4, 13, 14, 15, 16

The Jayachandran 2017 review framing remains accurate as far as it goes: edible mushrooms consistently promote health through gut microbiota modulation, and that modulation appears to be one of the primary mechanisms rather than a side effect.^[6] The step that framing does not license is the leap from "modulates gut microbiota" to "improves brain function in people."

Practical Context

Low

Culinary mushrooms are low-risk food; mushroom supplements are a different question

Concern

The gut-brain framing invites people experiencing depression, anxiety or cognitive decline to treat mushroom products as a mood intervention, and to escalate from food to concentrated extracts on the assumption that more beta-glucan means more benefit. No human trial supports a brain or mood outcome from mushroom prebiotics, and the one human beta-glucan RCT that looked for clinical change over eight weeks found none.

What the research says

Eating culinary mushrooms is ordinary, well-tolerated dietary behaviour and needs no special caution for most people. Concentrated extracts are a separate risk category: they are not required by any evidence discussed here, doses used in research vary widely, and rapid increases in fermentable fiber commonly cause gas, bloating and cramping — an effect specifically noted as a problem for people with IBS. Anyone treating a diagnosed mood, cognitive or gastrointestinal condition should raise supplement use with their clinician, particularly alongside existing medication.

Particularly relevant for: Readers considering mushrooms or mushroom extracts for mood or cognitive reasons

What to do

Treat culinary mushrooms as food, not as a mood treatment, and discuss concentrated extracts with a clinician before starting — especially alongside psychiatric or gastrointestinal medication.

Morales et al., Eur J Nutr, 2021 (no clinical marker change at 3.5 g/day beta-glucan over 8 weeks); Van den Abbeele et al., Int J Mol Sci, 2025 (fiber-related gas production in IBS)

This article describes research findings and is not medical advice. Nothing here is a recommendation to treat, prevent or manage any condition, and it should not be used to replace or delay care from a qualified clinician.

For the SCFA production mechanism in detail, see Mushroom Dietary Fiber and Short-Chain Fatty Acid Production. For serotonin and neurotransmitter production specifically, see Mushrooms, Gut Bacteria, and Neurotransmitter Production.

The Bottom Line

Mushroom prebiotics are proposed to influence brain function through a four-step pathway: non-digestible beta-glucans and chitin travel to the colon, gut bacteria ferment them into short-chain fatty acids (especially butyrate), butyrate crosses the blood-brain barrier, and butyrate then reduces neuroinflammation and upregulates BDNF. The four links are not equally evidenced. Human data is strong through the fermentation step — a 4-week trial in 80 adults found significantly higher intestinal butyrate on a mushroom diet (p = 0.001, Hedges' g = 0.824), and a double-blind RCT in 52 adults shifted colonic microbiota with shiitake beta-glucan (though it changed no cholesterol or inflammatory marker). The butyrate-to-brain step is imported from general gut-brain neuroscience and has never been measured after mushroom feeding. The brain endpoint itself rests on a single mouse study, in which 5% white button/portobello mushroom diets prevented stress-induced brain oxidative stress while shifting SCFA-producing bacteria — an association the study design cannot show to be causal. No controlled human trial has followed the chain from mushroom intake to a brain outcome.

Frequently Asked Questions

What is a prebiotic and how is it different from a probiotic?

A probiotic is a live microorganism (a beneficial bacterium) that you consume directly — it adds bacteria to your gut. A prebiotic is a non-digestible food component that feeds the bacteria already in your gut, selectively promoting beneficial populations. Mushroom beta-glucans, chitin, and other structural polysaccharides are prebiotics: they pass undigested into the colon where gut bacteria ferment them, producing short-chain fatty acids as the primary metabolic output. Probiotics add bacteria; prebiotics feed them.

How do prebiotics affect brain function?

The proposed route is short-chain fatty acid production. When gut bacteria ferment prebiotic fibers (including mushroom beta-glucans), they produce SCFAs — especially butyrate, propionate, and acetate. Butyrate crosses the blood-brain barrier, where it inhibits HDAC enzymes (increasing BDNF gene expression), suppresses neuroinflammatory pathways (reducing IL-6 and TNF-alpha), and supports hippocampal plasticity. Reduced abundance of butyrate-producing bacteria has been reported in depression populations, which is part of why prebiotic dietary interventions are being investigated for mood support. It is worth being precise about what is established here: the butyrate-to-brain mechanism comes from research on butyrate and on gut-brain signalling generally, not from mushroom studies, and the depression association is correlational. No trial has shown that eating mushroom prebiotics changes a brain or mood outcome in humans.

Which mushrooms act as prebiotics?

All edible mushrooms contain non-digestible fiber components (beta-glucans, chitin, hemicellulose) that act as prebiotics to varying degrees. Turkey tail, oyster mushroom, king oyster, reishi, and shiitake have the most research documentation for specific gut microbiota effects, and shiitake beta-glucan is the one tested in a double-blind human RCT. Even common culinary mushrooms — white button (Agaricus bisporus) and portobello — showed brain protection alongside a microbiota shift in a 2022 mouse study, though that study could not prove the gut change caused the brain change. The evidence covers mushrooms broadly as a food category, not just specialized medicinal species.

What are short-chain fatty acids and why do they matter for the brain?

Short-chain fatty acids are small molecules produced when gut bacteria ferment dietary fiber. The three primary ones are butyrate (4 carbons), propionate (3 carbons), and acetate (2 carbons). Butyrate is the most brain-relevant: it crosses the blood-brain barrier via monocarboxylate transporters, where it acts as an HDAC inhibitor (a gene expression regulator), increases BDNF production, and reduces the inflammatory signaling that is elevated in depression and cognitive decline. Adequate gut bacteria production of butyrate is associated with better mood, cognitive function, and neurological health in observational research.

Is there human evidence that mushrooms improve brain function through the gut?

Not for the brain outcome itself. There is good human evidence for the first half of the pathway: a 4-week parallel-group trial in 80 healthy adults found significantly higher intestinal butyrate on a mushroom-containing diet than placebo (p = 0.001), and a randomised double-blind trial in 52 adults found that shiitake-derived beta-glucan measurably shifted colonic microbiota. But neither trial measured cognition, mood, or any neurological marker. The only brain-level result comes from mice. So the accurate statement is that mushrooms demonstrably change human gut fermentation in the direction the pathway requires, and that no human trial has yet followed that change through to a brain outcome.

Do beta-glucans in mushrooms feed gut bacteria?

Yes. Mushroom beta-glucans are not broken down by human digestive enzymes and pass intact to the large intestine, where gut bacteria that express the relevant glycolytic enzymes ferment them. This fermentation selectively enriches specific bacterial populations — particularly SCFA-producing species in the Akkermansiaceae, Tannerellaceae, Bifidobacterium, and Ruminococcus families. The fermentation products (primarily butyrate, propionate, and acetate) are the downstream output of this bacterial activity.

Sources & References

1. 1RTHM-01921·Kulshreshtha, Shweta (2024). “Mushroom as Prebiotics: a Sustainable Approach for Healthcare..” Probiotics and antimicrobial proteins.Study breakdown →PubMed →↩
2. 2RTHM-01308·Yin, Chaomin et al. (2020). “The Impact of Mushroom Polysaccharides on Gut Microbiota and Its Beneficial Effects to Host: A Review..” Carbohydrate polymers.Study breakdown →PubMed →↩
3. 3RTHM-00573·Yu, Zhuo-Teng et al. (2013). “Trametes versicolor extract modifies human fecal microbiota composition in vitro..” Plant foods for human nutrition (Dordrecht.Study breakdown →PubMed →↩
4. 4RTHM-01520·García-Sanmartín, Josune et al. (2022). “Agaricus Mushroom-Enriched Diets Modulate the Microbiota-Gut-Brain Axis and Reduce Brain Oxidative Stress in Mice..” Antioxidants (Basel.Study breakdown →PubMed →↩
5. 5RTHM-01577·Ma, Gaoxing et al. (2022). “Health benefits of edible mushroom polysaccharides and associated gut microbiota regulation..” Critical reviews in food science and nutrition.Study breakdown →PubMed →↩
6. 6RTHM-00878·Jayachandran, Muthukumaran et al. (2017). “A Critical Review on Health Promoting Benefits of Edible Mushrooms through Gut Microbiota..” International journal of molecular sciences.Study breakdown →PubMed →↩
7. 7RTHM-01242·Liu, Xiaoxiao et al. (2020). “A Review on Linking the Medicinal Functions of Mushroom Prebiotics with Gut Microbiota..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
8. 8RTHM-01829·Yu, Changxia et al. (2023). “The Effect of Mushroom Dietary Fiber on the Gut Microbiota and Related Health Benefits: A Review..” Journal of fungi (Basel.Study breakdown →PubMed →↩
9. 9RTHM-01835·Zhao, Jiahui et al. (2023). “The Interaction between Mushroom Polysaccharides and Gut Microbiota and Their Effect on Human Health: A Review..” Biology.Study breakdown →PubMed →↩
10. 10RTHM-00644·Nguepi, Tsopmejio Ivan Steve et al. (2020). “Mushrooms Bioactive as Prebiotics to Modulate Gut Microbiota in Relationships with Causes and Prevention of Liver Diseases (Review)..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
11. 11RTHM-00855·Törős, Gréta et al. (2023). “Modulation of the Gut Microbiota with Prebiotics and Antimicrobial Agents from Pleurotus ostreatus Mushroom..” Foods (Basel.Study breakdown →PubMed →↩
12. 12RTHM-01836·Zhao, Qilong et al. (2023). “The benefits of edible mushroom polysaccharides for health and their influence on gut microbiota: a review..” Frontiers in nutrition.Study breakdown →PubMed →↩
13. 13RTHM-01593·Nishimoto, Yuichiro et al. (2022). “Dietary supplement of mushrooms promotes SCFA production and moderately associates with IgA production: A pilot clinical study..” Frontiers in nutrition.Study breakdown →PubMed →↩
14. 14RTHM-01408·Morales, Diego et al. (2021). “Modulation of human intestinal microbiota in a clinical trial by consumption of a β-D-glucan-enriched extract obtained from Lentinula edodes..” European journal of nutrition.Study breakdown →PubMed →↩
15. 15RTHM-02197·Van den Abbeele, Pieter et al. (2025). “Triacetin and a Mushroom Blend Restore Butyrate Production by IBS Microbiomes Ex Vivo, Thus Promoting Barrier Integrity..” International journal of molecular sciences.Study breakdown →PubMed →↩
16. 16RTHM-02104·Kerezoudi, Evangelia N et al. (2025). “Pleurotus eryngii Mushrooms Fermented with Human Fecal Microbiota Protect Intestinal Barrier Integrity: Immune Modulation and Signalling Pathways Counter Deoxycholic Acid-Induced Disruption in Healthy Colonic Tissue..” Nutrients.Study breakdown →PubMed →↩